Metagenomi Inc
MGX1.760USD
+0.100+6.02%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
66.08MMarket Cap
LossP/E TTM
More Details of Metagenomi Inc Company
Metagenomi, Inc. is a precision genetic medicine company. The Company is focused on developing curative therapeutics for patients using its comprehensive metagenomics derived toolbox. Its diverse and modular genome editing toolbox is designed to precisely target any site in the human genome. Its comprehensive genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, including prime editing systems and clustered regularly interspaced short palindromic repeat (CRISPR)-associated transposases (CASTs). It has also developed a modular toolbox of genome editing systems that will allow it to interact with the human genome in a site-specific manner, where each tool can be matched to specific disease targets. The Company uses artificial intelligence and its metagenomics platform to develop curative genetic medicines.
Metagenomi Inc Info
Ticker SymbolMGX
Company nameMetagenomi Inc
IPO dateFeb 09, 2024
CEOIrish (Jian)
Number of employees202
Security typeOrdinary Share
Fiscal year-endFeb 09
Address5959 Horton St
CityEMERYVILLE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94608
Phone15108714880
Websitehttps://metagenomi.co/
Ticker SymbolMGX
IPO dateFeb 09, 2024
CEOIrish (Jian)
Company Executives of Metagenomi Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Brian C. Thomas, Ph.D.
Dr. Brian C. Thomas, Ph.D.
Co-Founder, Director
Co-Founder, Director
2.36M
-0.16%
Dr. Jian Irish, Ph.D.
Dr. Jian Irish, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
824.33K
+42.76%
Dr. Sarah B. Noonberg, M.D., Ph.D.
Dr. Sarah B. Noonberg, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
109.14K
-4.58%
Mr. Laurence E. Reid, Ph.D.
Mr. Laurence E. Reid, Ph.D.
Director
Director
--
--
,
,
Senior Vice President, Head of Legal, Compliance Officer and Corporate Secretary
Senior Vice President, Head of Legal, Compliance Officer and Corporate Secretary
--
--
Dr. Juergen Eckhardt, M.D.
Dr. Juergen Eckhardt, M.D.
Independent Director
Independent Director
--
--
Ms. Pamela M. (Pam) Wapnick
Ms. Pamela M. (Pam) Wapnick
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Eric H. Bjerkholt
Mr. Eric H. Bjerkholt
Independent Director
Independent Director
--
--
Dr. Willard H. Dere, M.D.
Dr. Willard H. Dere, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Brian C. Thomas, Ph.D.
Dr. Brian C. Thomas, Ph.D.
Co-Founder, Director
Co-Founder, Director
2.36M
-0.16%
Dr. Jian Irish, Ph.D.
Dr. Jian Irish, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
824.33K
+42.76%
Dr. Sarah B. Noonberg, M.D., Ph.D.
Dr. Sarah B. Noonberg, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
109.14K
-4.58%
Mr. Laurence E. Reid, Ph.D.
Mr. Laurence E. Reid, Ph.D.
Director
Director
--
--
,
,
Senior Vice President, Head of Legal, Compliance Officer and Corporate Secretary
Senior Vice President, Head of Legal, Compliance Officer and Corporate Secretary
--
--
Dr. Juergen Eckhardt, M.D.
Dr. Juergen Eckhardt, M.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Bayer HealthCare LLC
10.79%
Thomas (Brian C)
6.29%
Humboldt Capital, LLC
5.05%
The Vanguard Group, Inc.
3.31%
Bernales (Sebastian Ph.D.)
3.12%
Other
71.44%
Shareholders
Shareholders
Proportion
Bayer HealthCare LLC
10.79%
Thomas (Brian C)
6.29%
Humboldt Capital, LLC
5.05%
The Vanguard Group, Inc.
3.31%
Bernales (Sebastian Ph.D.)
3.12%
Other
71.44%
Shareholder Types
Shareholders
Proportion
Corporation
15.85%
Individual Investor
13.45%
Investment Advisor
7.83%
Hedge Fund
3.18%
Venture Capital
3.00%
Investment Advisor/Hedge Fund
1.70%
Research Firm
1.39%
Sovereign Wealth Fund
0.67%
Other
52.93%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
156
7.24M
19.30%
-9.50M
2025Q2
159
20.26M
54.19%
-7.71M
2025Q1
157
20.44M
54.67%
-7.64M
2024Q4
143
21.51M
57.48%
-2.78M
2024Q3
116
23.74M
63.40%
-1.13M
2024Q2
94
26.05M
69.54%
+4.67M
2024Q1
65
26.68M
71.20%
+16.22M
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Bayer HealthCare LLC
4.05M
10.79%
--
--
Sep 30, 2024
Thomas (Brian C)
2.37M
6.31%
-10.79K
-0.45%
Jun 06, 2025
Humboldt Capital, LLC
1.90M
5.05%
--
--
Apr 14, 2025
The Vanguard Group, Inc.
1.26M
3.35%
-199.55K
-13.69%
Jun 30, 2025
Bernales (Sebastian Ph.D.)
1.17M
3.12%
--
--
Apr 14, 2025
Irish (Jian)
579.04K
1.54%
-6.39K
-1.09%
Jun 06, 2025
Sozo Ventures LLC
581.58K
1.55%
--
--
Jun 30, 2025
Catalio Capital Management, LP
528.99K
1.41%
--
--
Jun 30, 2025
Peapod Lane Capital LLC
508.11K
1.35%
+155.65K
+44.16%
Jun 30, 2025
Millennium Management LLC
383.03K
1.02%
+197.93K
+106.92%
Jun 30, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
iShares Micro-Cap ETF
0.01%
Avantis US Small Cap Equity ETF
0%
iShares Russell 2000 Value ETF
0%
Proshares Ultra Russell 2000
0%
ProShares Hedge Replication ETF
0%
Global X Russell 2000 ETF
0%
Schwab U.S. Small-Cap ETF
0%
iShares Russell 2000 ETF
0%
ProShares UltraPro Russell2000
0%
iShares Russell 2000 Growth ETF
0%
iShares Micro-Cap ETF
Proportion0.01%
Avantis US Small Cap Equity ETF
Proportion0%
iShares Russell 2000 Value ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
Schwab U.S. Small-Cap ETF
Proportion0%
iShares Russell 2000 ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Metagenomi Inc?
The top five shareholders of Metagenomi Inc are:
Bayer HealthCare LLC holds 4.05M shares, accounting for 10.79% of the total shares.
Thomas (Brian C) holds 2.37M shares, accounting for 6.31% of the total shares.
Humboldt Capital, LLC holds 1.90M shares, accounting for 5.05% of the total shares.
The Vanguard Group, Inc. holds 1.26M shares, accounting for 3.35% of the total shares.
Bernales (Sebastian Ph.D.) holds 1.17M shares, accounting for 3.12% of the total shares.
Bayer HealthCare LLC holds 4.05M shares, accounting for 10.79% of the total shares.
Thomas (Brian C) holds 2.37M shares, accounting for 6.31% of the total shares.
Humboldt Capital, LLC holds 1.90M shares, accounting for 5.05% of the total shares.
The Vanguard Group, Inc. holds 1.26M shares, accounting for 3.35% of the total shares.
Bernales (Sebastian Ph.D.) holds 1.17M shares, accounting for 3.12% of the total shares.
What are the top three shareholder types of Metagenomi Inc?
The top three shareholder types of Metagenomi Inc are:
Bayer HealthCare LLC
Thomas (Brian C)
Humboldt Capital, LLC
Bayer HealthCare LLC
Thomas (Brian C)
Humboldt Capital, LLC
How many institutions hold shares of Metagenomi Inc (MGX)?
As of 2025Q3, 156 institutions hold shares of Metagenomi Inc, with a combined market value of approximately 7.24M, accounting for 19.30% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -34.89%.
What is the biggest source of revenue for Metagenomi Inc?
In --, the -- business generated the highest revenue for Metagenomi Inc, amounting to -- and accounting for --% of total revenue.
